CAS NO: | 1452-77-3 |
规格: | ≥98% |
包装 | 价格(元) |
1g | 电议 |
2g | 电议 |
5g | 电议 |
10g | 电议 |
25g | 电议 |
100g | 电议 |
Molecular Weight (MW) | 122.12 |
---|---|
Formula | C6H6N2O |
CAS No. | 1452-77-3 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 24 mg/mL (196.5 mM) |
Water: 24 mg/mL (196.5 mM) | |
Ethanol: 24 mg/mL (196.5 mM) | |
Other info | SMILES: NC(=O)c1ccccn1 InChI: 1S/C6H6N2O/c7-6(9)5-3-1-2-4-8-5/h1-4H,(H2,7,9) InChI key: IBBMAWULFFBRKK-UHFFFAOYSA-N |
Synonyms | 2-Pyridinecarboxamide, Picolinoylamide, 2-Carbamoylpyridine |
In Vitro | In vitro activity: Overnight treatment of rats with picolinamide, administered as a single injection (4 mmol/kg), inhibits Na+/phosphate cotransport by isolated renal brush border membrane vesicles. There is only a small increase (1.5-fold) in renal cortical NAD content after picolinamide treatment. Cell Assay: The pathway of oxidation of picolinamide by a Gram-negative rod has been elucidated. Results showed that under high pH conditions, whole cells could release 2,5-dihydroxypyridine into culture supernatants. Moreover, sodium arsenite was able to cause whole cells to accumulate 6-hydroxypicolinate in the culture media. In addition, whole cells were found to oxidize picolinamide, without lag. It was also found that cell-free extracts could convert picolinamide into picolinate, and hydroxylate picolinate into 6-hydroxypicolinate. |
---|---|
In Vivo | Picolinamide was used in a previous study to evaluate the possibility that the inhibition of Na+/phosphate cotransport might be associated with the inhibition of NAD hydrolyzing enzymes. Results showed that the overnight treatment of rats with picolinamide, administered as a single injection (4 mmol/kg), could inhibit Na+/phosphate cotransport by isolated renal brush border membrane vesicles. Similar to nicotinamide, the inhibition caused by picolinamide occurred in thyroparathyroidectomized rats, was specific for Na+/phosphate cotransport. Unlike nicotinamide, there was only a small 1.5-fold increase in renal cortical NAD content after picolinamide treatment. |
Animal model | Wistar rats |
Formulation & Dosage | Dissolved in 0.9% NaCl solution; 250 mg/kg; i.p. injection |
References | Cancer Res. 1985 Apr;45(4):1845-9; J Biol Chem. 1982 Jun 10;257(11):6084-8; J Pharmacol Exp Ther. 1989 Oct;251(1):188-92. |